KMG Fiduciary Partners LLC grew its position in Pfizer Inc. (NYSE:PFE) by 27.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 31,871 shares of the biopharmaceutical company’s stock after acquiring an additional 6,864 shares during the quarter. KMG Fiduciary Partners LLC’s holdings in Pfizer were worth $1,185,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Global Trust Asset Management LLC grew its stake in Pfizer by 14.5% during the fourth quarter. Global Trust Asset Management LLC now owns 51,277 shares of the biopharmaceutical company’s stock worth $1,888,000 after buying an additional 6,476 shares during the period. Acropolis Investment Management LLC lifted its stake in shares of Pfizer by 6.4% in the fourth quarter. Acropolis Investment Management LLC now owns 12,151 shares of the biopharmaceutical company’s stock worth $447,000 after acquiring an additional 736 shares in the last quarter. Cox Capital Mgt LLC increased its holdings in Pfizer by 4.7% during the 4th quarter. Cox Capital Mgt LLC now owns 57,642 shares of the biopharmaceutical company’s stock worth $2,122,000 after purchasing an additional 2,596 shares during the last quarter. Baugh & Associates LLC boosted its stake in shares of Pfizer by 3.6% during the 4th quarter. Baugh & Associates LLC now owns 103,448 shares of the biopharmaceutical company’s stock valued at $3,808,000 after buying an additional 3,576 shares during the last quarter. Finally, Bath Savings Trust Co grew its position in shares of Pfizer by 14.4% during the fourth quarter. Bath Savings Trust Co now owns 22,182 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 2,791 shares in the last quarter. 69.08% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently commented on PFE shares. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating and set a $37.00 price target on the stock in a report on Thursday, October 29th. JPMorgan Chase & Co. set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, November 9th. Mizuho lifted their target price on shares of Pfizer from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price objective on the stock. Finally, TheStreet raised Pfizer from a “c+” rating to a “b-” rating in a research note on Wednesday, November 25th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $39.87.
In related news, major shareholder Pfizer Inc purchased 1,200,000 shares of the business’s stock in a transaction on Tuesday, October 27th. The stock was acquired at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the purchase, the insider now directly owns 27,349,211 shares in the company, valued at $273,492,110. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.08% of the stock is currently owned by insiders.
PFE stock traded down $0.36 during trading on Wednesday, reaching $36.82. The stock had a trading volume of 787,109 shares, compared to its average volume of 36,397,031. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $204.66 billion, a price-to-earnings ratio of 14.75, a P/E/G ratio of 3.10 and a beta of 0.66. The company’s 50 day moving average is $38.24 and its two-hundred day moving average is $37.16. Pfizer Inc. has a one year low of $27.88 and a one year high of $43.08.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $12.13 billion for the quarter, compared to analysts’ expectations of $12.30 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. Pfizer’s revenue was down 4.3% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.84 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be paid a $0.39 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a yield of 4.24%. The ex-dividend date is Thursday, January 28th. Pfizer’s dividend payout ratio is currently 51.53%.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Recommended Story: Key terms to understand channel trading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.